Welcome to our dedicated page for PRECISION PEPTID news (Ticker: PNGAF), a resource for investors and traders seeking the latest updates and insights on PRECISION PEPTID stock.
The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.
Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of its peptide products.
This builds on its 503A U.S. sterile compounding deal and creates nationwide prescription-based peptide access ahead of the July 23, 2026 PCAC review of BPC-157 and other peptides.
Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) extended its investor relations agreement with Emerging Markets Consulting (EMC) for another six-month term starting June 8, 2026.
The extension fee is USD $150,000, with no stock options issued. EMC will continue providing design, development, and dissemination investor communication services.
The Precision Peptide Company (OTCQB: PNGAF) signed a compounding agreement with a U.S.-based 503A sterile pharmacy for prescription preparation and fulfillment of peptide products, including BPC-157.
The partner can fulfill up to about 25,000 prescriptions per day, all 100% compounded in the United States, with activities expected to start June 1, 2026.
The agreement is intended to strengthen the U.S. supply chain and regulatory footprint amid evolving FDA and PCAC review of peptide substances. The company also settled $125,000 of CEO bonus debt through issuing 300,000 shares at $0.42, subject to a four‑month plus one day hold period.
The Precision Peptide Company (OTCQB: PNGAF, CSE: BPC) will exhibit at Dave Asprey's BEYOND 2026 biohacking, longevity, and consciousness conference in Austin, Texas, from May 27-29, 2026.
The company will be the only peptide company exhibiting, showcasing its peptide product line, including a needle-free BPC-157 transdermal patch, to over 5,000 attendees. This event precedes CSO Justin Kirkland's June 2026 feature on The Human Upgrade with Dave Asprey, further positioning the brand before an engaged peptide-focused wellness audience.
The Precision Peptide Company (OTCQB: PNGAF) placed an order for 20,000 BPC-157 transdermal patches, its lead product candidate, to support planned commercial release.
Each needle-free patch is formulated to deliver 2 mg BPC-157, with independent tests confirming 95.5% purity and a measured 2.02 mg dose per patch. Initial online sales could start June 2026.
The Precision Peptide Company (OTCQB: PNGAF) expanded details of its exclusive peptide marketing partnership with MMA.INC (NYSE American: MMA), gaining direct access to MMA.INC’s global combat sports ecosystem.
The agreement features a 50/50 net revenue share in year one, then 75/25 for Precision, U.S.-manufactured, third-party tested products, and exposure to over 5 million followers, 530,000 user profiles and 800+ verified gyms across 16 countries.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) reported independent lab data for its lead BPC-157 transdermal patch. Miraxis Labs confirmed 95.5% chromatographic purity and a 2.02 mg measured dose per patch using UHPLC-DAD, exceeding the ≥95% industry benchmark and supporting progression toward commercial launch, subject to further testing, scale-up and regulatory considerations.
The Precision Peptide Company (OTCQB: PNGAF) announced that Justin Kirkland, Co-Founder and Chief Scientific Officer of subsidiary Amino Innovations, will appear on The Human Upgrade with Dave Asprey. The episode, focused on peptide-based wellness and delivery formats, is scheduled for June 4, 2026.
The feature highlights Amino Innovations' needle-free BPC-157 transdermal patch development, the ongoing research collaboration with the University of Alberta's Drug Development and Innovation Centre, and a broader U.S. regulatory shift in favor of peptide therapies.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) entered an Exclusive Strategic Marketing Agreement with Mixed Martial Arts Group Limited on May 8, 2026. MMA will market BPC’s peptide products to its large global combat sports ecosystem.
MMA has over 5 million social followers, about 530,000 user profiles, more than 75,000 active students and 800+ verified gyms. Net revenue from MMA-sourced sales is shared 50%/50% in year one, then 75% to BPC and 25% to MMA thereafter. Products will be manufactured in the U.S. and comply with applicable FDA and other U.S. regulatory standards.
The Precision Peptide Company (OTCQB: PNGAF) reports progress on a needle-free BPC-157 transdermal patch, now in active testing with near-term results expected. Subject to satisfactory tests, the company plans to advance the patch toward commercial release as part of a multi-product transdermal platform under Amino Innovations.
The patch is designed for sustained skin delivery to lower needle aversion barriers. A second TA-1 immune patch is in development. Testing is supported by a research services agreement with the University of Alberta. The company cautions there is no assurance testing or commercialization will succeed or produce revenue.